Neurocrine to acquire Soleno in $2.9bn transaction

Neurocrine Biosciences has signed a definitive statement to get Soleno Therapeutics for $53.00 per stock successful cash, which represents $2.9bn successful full transaction equity value.

The transaction volition grow Neurocrine’s portfolio successful endocrinology and uncommon diseases via the summation of Soleno’s pb product, Vykat XR (diazoxide choline), for Prader-Willi syndrome (PWS).

Vykat XR is simply a first-in-class therapy approved by the US Food and Drug Administration (FDA) for hyperphagia, the cardinal grounds of the uncommon familial upset PWS.

Following its US motorboat successful the 2nd 4th of 2025, the therapy generated revenues of $190m, with $92m successful the 4th fourth unsocial for Soleno.

Neurocrine’s broader infrastructure is expected to summation Vykat XR’s scope and efficacy.

PWS is marked by behavioural, neurological, and metabolic dysfunctions, peculiarly hyperphagia.

The acquisition volition alteration Neurocrine to connection 3 marketed first-in-class therapies: Ingrezza for tardive dyskinesia and Huntington’s chorea, Crenessity for congenital adrenal hyperplasia, and Vykat XR for PWS. Intellectual spot protections for Vykat XR are expected to past into the mid-2040s.

The transaction volition beryllium financed done disposable currency and pre-payable debt. Neurocrine volition commence a currency tender connection for each Soleno shares, reflecting a 34% premium implicit the closing stock price.

The statement is taxable to customary conditions and regulatory approvals, with an expected adjacent wrong 90 days.

Neurocrine Biosciences CEO Kyle Gano said: “This transaction volition beforehand Neurocrine’s ngo to present life-changing treatments portion accelerating our gross maturation and portfolio diversification strategy.

“We stock the Soleno team’s heavy committedness to the Prader-Willi syndrome assemblage and look guardant to leveraging our acquisition and capabilities to grow Vykat XR’s scope to payment much patients, portion further strengthening Neurocrine’s enactment successful delivering transformative medicines”.

In 2024, the FDA approved an alternate formulation for Neurocrine’s Huntington’s illness therapy, Ingrezza.

"Neurocrine to get Soleno successful $2.9bn transaction" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.